The Company has received approval to list its common shares on the Nasdaq Capital Market under the symbol “ACOG” and is ...

“We also announced that the FDA has approved our IDE application allowing us to move ... InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information ...

The FDA has granted Jan123 Orphan ... and its Nasdaq ticker symbol was updated to ALTS. On August 26, 2024, the Company appointed Peter Tassiopoulos as CEO. In October, the Board approved the ...

Change of the Company’s corporate name to Grace Therapeutics, Inc. The Company’s common stock commenced trading under the trading symbol “GRCE” on Nasdaq ... (A-T), for which there are currently no ...

Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS ... and the Company’s existing ...

Discover the cutting-edge Apple Intelligence features introduced in iOS 18.1 that enhance user experience and functionality.

the expected nature and timing of the Company's planned FDA submission and related plans for clinical study amendment, whether the Company's cash position will be sufficient to fund operations needed ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised ...

In August, the FDA approved Ascendis Pharma’s Yorvipath ... it snagged the fitting stock symbol “GPCR”). Lead Structure drug candidate GSBR-1290 is currently in mid-stage clinical ...

FDA's Human Foods Program released its 2025 Priority Deliverables today, which details the primary focuses for its first year under the reorganization. Highlights include a goal to issue guidance on ...

Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – ...